TG Therapeutics (NASDAQ:TGTX) is up 17% premarket on light volume on the heels of positive results from a Phase 2b clinical trial, UNITY-NHL, evaluating umbralisib in patients with treatment-resistant non-Hodgkin lymphoma (NHL).
The study med the primary endpoint of overall response rate (ORR) and met the company’s target guidance of 40 – 50% ORR.
Preliminary data will be presented at AACR on April 1. Complete results will be submitted for presentation at a future medical conference (a certainty that it will be ASCO in May/June).
Management will host a conference call this morning at 8:30 am ET to discuss the results.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.